Get started
Author

Roberta Joppi

Observed names: Joppi R., Joppi, Roberta, R Joppi, R. Joppi
Observed institutions: Mario Negri Institute for Pharmacological Research, Ospedale di Bolzano, Cineca, Regione del Veneto, Azienda ULSS 9 Scaligera, Azienda Sanitaria dell'Alto Adige
ORCID: 0000-0002-9085-3626
Observed ORCIDs: 0000-0002-9085-3626, 0009-0006-3842-9728
OpenAlex ID: A5079498687
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets
2018 · Brian Godman, Anna Bucsics, et al. · Frontiers in Public Health · 167
PDF
Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications
2010 · Brian Godman, William Shrank, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 161
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?
2014 · Brian Godman, Rickard E Malmström, et al. · Expert Review of Clinical Pharmacology · 124
Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU
2012 · Roberta Joppi, Vittorio Bertele’, et al. · European Journal of Clinical Pharmacology · 119
Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries
2018 · Tomasz Bochenek, Vafa Abilova, et al. · Frontiers in Pharmacology · 118
PDF
Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications
2011 · Brian Godman, William Shrank, et al. · Frontiers in Pharmacology · 113
PDF
Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures
2005 · G Apolone, R Joppi, et al. · British Journal of Cancer · 105
PDF
Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
2010 · Brian Godman, William Shrank, et al. · Pharmaceuticals · 94
PDF
Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs
2013 · Rickard E. Malmström, Brian B. Godman, et al. · Frontiers in Pharmacology · 91
PDF
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
2021 · Brian Godman, Andrew Hill, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 83
PDF
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
2021 · Evelien Moorkens, Brian Godman, et al. · Frontiers in Pharmacology · 76
PDF
Orphan drug development is progressing too slowly
2006 · Roberta Joppi, Vittorio Bertele, et al. · British Journal of Clinical Pharmacology · 72
PDF
Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval
2019 · Roberta Joppi, Vittorio Bertele, et al. · British Journal of Clinical Pharmacology · 66
PDF
Orphan drug development is not taking off
2009 · Roberta Joppi, Vittorio Bertele, et al. · British Journal of Clinical Pharmacology · 66
PDF
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways
2016 · Michael Ermisch, Anna Bucsics, et al. · Frontiers in Pharmacology · 56
PDF
Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA
2019 · Patricia Vella Bonanno, Anna Bucsics, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 51
PDF
Having Your Cake and Eating It: Office of Fair Trading Proposal for Funding New Drugs to Benefit Patients and Innovative Companies
2008 · Brian Godman, Alan Haycox, et al. · PharmacoEconomics · 51
Pricing of oral generic cancer medicines in 25 European countries; findings and implications
2019 · Brian Godman, Andrew Hill, et al. · Generics and Biosimilars Initiative Journal · 48
PDF
Disappointing biotech
2005 · Roberta Joppi, Vittorio Bertele, et al. · BMJ · 47
PDF
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation
2017 · Patricia Vella Bonanno, Michael Ermisch, et al. · Frontiers in Pharmacology · 46
PDF
Letting post-marketing bridge the evidence gap: the case of orphan drugs: Table 1
2016 · Roberta Joppi, Chiara Gerardi, et al. · BMJ · 46
Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs
2014 · Brian Godman, Rickard E. Malmström, et al. · Frontiers in Pharmacology · 45
PDF
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future
2016 · Winnie de Bruijn, Cristina Ibáñez, et al. · Frontiers in Pharmacology · 30
PDF
Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: A population-based study
2013 · R. Joppi, E. Cinconze, et al. · European Journal of Internal Medicine · 27
The Italian Horizon Scanning Project
2009 · on behalf of the Italian Horizon Scanning Project Group, Roberta Joppi, et al. · European Journal of Clinical Pharmacology · 27
Works count: 60
Citation count: 1,989
H-index: 25
I10-index: 26
Year
Topic
Type